Skip to main content

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.

Publication ,  Journal Article
Hassett, MJ; Silver, SM; Hughes, ME; Blayney, DW; Edge, SB; Herman, JG; Hudis, CA; Marcom, PK; Pettinga, JE; Share, D; Theriault, R; Wong, Y-N ...
Published in: J Clin Oncol
June 20, 2012

PURPOSE: Gene expression profile (GEP) testing is a relatively new technology that offers the potential of personalized medicine to patients, yet little is known about its adoption into routine practice. One of the first commercially available GEP tests, a 21-gene profile, was developed to estimate the benefit of adjuvant chemotherapy for hormone receptor-positive breast cancer (HR-positive BC). PATIENTS AND METHODS: By using a prospective registry data set outlining the routine care provided to women diagnosed from 2006 to 2008 with HR-positive BC at 17 comprehensive and community-based cancer centers, we assessed GEP test adoption and the association between testing and chemotherapy use. RESULTS: Of 7,375 women, 20.4% had GEP testing and 50.2% received chemotherapy. Over time, testing increased (14.7% in 2006 to 27.5% in 2008; P < .01) and use of chemotherapy decreased (53.9% in 2006 to 47.0% in 2008; P < .01). Characteristics independently associated with lower odds of testing included African American versus white race (odds ratio [OR], 0.70; 95% CI, 0.54 to 0.92) and high school or less versus more than high school education (OR, 0.63; 95% CI, 0.52 to 0.76). Overall, testing was associated with lower odds of chemotherapy use (OR, 0.70; 95% CI, 0.62 to 0.80). Stratified analyses demonstrated that for small, node-negative cancers, testing was associated with higher odds of chemotherapy use (OR, 11.13; 95% CI, 5.39 to 22.99), whereas for node-positive and large node-negative cancers, testing was associated with lower odds of chemotherapy use (OR, 0.11; 95% CI, 0.07 to 0.17). CONCLUSION: There has been a progressive increase in use of this GEP test and an associated shift in the characteristics of and overall reduction in the proportion of women with HR-positive BC receiving adjuvant chemotherapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

June 20, 2012

Volume

30

Issue

18

Start / End Page

2218 / 2226

Location

United States

Related Subject Headings

  • Young Adult
  • White People
  • Time Factors
  • Receptors, Estrogen
  • Oncology & Carcinogenesis
  • Neoplasms, Hormone-Dependent
  • Middle Aged
  • Humans
  • Healthcare Disparities
  • Gene Expression Profiling
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hassett, M. J., Silver, S. M., Hughes, M. E., Blayney, D. W., Edge, S. B., Herman, J. G., … Weeks, J. C. (2012). Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol, 30(18), 2218–2226. https://doi.org/10.1200/JCO.2011.38.5740
Hassett, Michael J., Samuel M. Silver, Melissa E. Hughes, Douglas W. Blayney, Stephen B. Edge, James G. Herman, Clifford A. Hudis, et al. “Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.J Clin Oncol 30, no. 18 (June 20, 2012): 2218–26. https://doi.org/10.1200/JCO.2011.38.5740.
Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012 Jun 20;30(18):2218–26.
Hassett, Michael J., et al. “Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.J Clin Oncol, vol. 30, no. 18, June 2012, pp. 2218–26. Pubmed, doi:10.1200/JCO.2011.38.5740.
Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong Y-N, Vandergrift JL, Niland JC, Weeks JC. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012 Jun 20;30(18):2218–2226.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

June 20, 2012

Volume

30

Issue

18

Start / End Page

2218 / 2226

Location

United States

Related Subject Headings

  • Young Adult
  • White People
  • Time Factors
  • Receptors, Estrogen
  • Oncology & Carcinogenesis
  • Neoplasms, Hormone-Dependent
  • Middle Aged
  • Humans
  • Healthcare Disparities
  • Gene Expression Profiling